UK biotech sector has shrugged off a difficult economic environment with a 44% increase in venture capital investment in the ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy ...

First teased earlier this year, the phase 3 CLARITY-Gastric01 study included previously treated patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or ...

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by 2nd February next year. If approved, the oral ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a report saying it has identified cases of serious liver injury – including deaths ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC ...

In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...